Dulaglutide outperforms 3 diabetes drugs in Phase III trial

10/25/2012 | Reuters

Data from a late-stage trial revealed the investigational once-weekly diabetes drug dulaglutide fared better than Byetta, oral metformin and Januvia in reducing blood glucose levels in patients. Gastrointestinal-related side effects were noted, but dulaglutide's overall safety profile was similar to findings seen in midstage trials, drugmaker Eli Lilly and Co. stated.

View Full Article in:


Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Vice President, Science and Regulatory Affairs
American Beverage Association
Washington, DC
Senior Manager of Medical Management
Network Health
Medford, MA
Columbus, OH
Manager, Medical Management
Network Health
Medford, MA
Executive Medical Director
Aspirus Network Inc
Wausau, WI